Mehta Analysis: Trump Pricing Tempest In A Teapot Is An Opportunity For Biopharma Leaders
Executive Summary
President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.